Next Article in Journal
Gli Proteins: Regulation in Development and Cancer
Next Article in Special Issue
RHOG Activates RAC1 through CDC42 Leading to Tube Formation in Vascular Endothelial Cells
Previous Article in Journal
C/EBPβ Is a Transcriptional Regulator of Wee1 at the G2/M Phase of the Cell Cycle
Previous Article in Special Issue
Overexpression of CDC42SE1 in A431 Cells Reduced Cell Proliferation by Inhibiting the Akt Pathway
Article Menu
Issue 2 (February) cover image

Export Article

Open AccessReview
Cells 2019, 8(2), 146; https://doi.org/10.3390/cells8020146

Focus on Cdc42 in Breast Cancer: New Insights, Target Therapy Development and Non-Coding RNAs

Department of Pathophysiology, Jiangxi Province Key Laboratory of Tumor Pathogenesis and Molecular Pathology, Medical College, Nanchang University, 461 Bayi Road, Nanchang 330006, China
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Received: 30 December 2018 / Revised: 30 January 2019 / Accepted: 8 February 2019 / Published: 11 February 2019
(This article belongs to the Special Issue Rho GTPases in Health and Disease)
Full-Text   |   PDF [2648 KB, uploaded 22 February 2019]   |  

Abstract

Breast cancer is the most common malignant tumors in females. Although the conventional treatment has demonstrated a certain effect, some limitations still exist. The Rho guanosine triphosphatase (GTPase) Cdc42 (Cell division control protein 42 homolog) is often upregulated by some cell surface receptors and oncogenes in breast cancer. Cdc42 switches from inactive guanosine diphosphate (GDP)-bound to active GTP-bound though guanine-nucleotide-exchange factors (GEFs), results in activation of signaling cascades that regulate various cellular processes such as cytoskeletal changes, proliferation and polarity establishment. Targeting Cdc42 also provides a strategy for precise breast cancer therapy. In addition, Cdc42 is a potential target for several types of non-coding RNAs including microRNAs and lncRNAs. These non-coding RNAs is extensively involved in Cdc42-induced tumor processes, while many of them are aberrantly expressed. Here, we focus on the role of Cdc42 in cell morphogenesis, proliferation, motility, angiogenesis and survival, introduce the Cdc42-targeted non-coding RNAs, as well as present current development of effective Cdc42-targeted inhibitors in breast cancer. View Full-Text
Keywords: breast cancer; Cdc42; cytoskeleton remodeling; tumor progression; targeted therapy; non-coding RNAs breast cancer; Cdc42; cytoskeleton remodeling; tumor progression; targeted therapy; non-coding RNAs
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Zhang, Y.; Li, J.; Lai, X.-N.; Jiao, X.-Q.; Xiong, J.-P.; Xiong, L.-X. Focus on Cdc42 in Breast Cancer: New Insights, Target Therapy Development and Non-Coding RNAs. Cells 2019, 8, 146.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cells EISSN 2073-4409 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top